Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 145


Vaccine-induced mucosal immunity to poliovirus: analysis of cohorts from an open-label, randomised controlled trial in Latin American infants.

Wright PF, Connor RI, Wieland-Alter WF, Hoen AG, Boesch AW, Ackerman ME, Oberste MS, Gast C, Brickley EB, Asturias EJ, Rüttimann R, Bandyopadhyay AS.

Lancet Infect Dis. 2016 Dec;16(12):1377-1384. doi: 10.1016/S1473-3099(16)30169-4. Epub 2016 Sep 13.


Humoral and intestinal immunity induced by new schedules of bivalent oral poliovirus vaccine and one or two doses of inactivated poliovirus vaccine in Latin American infants: an open-label randomised controlled trial.

Asturias EJ, Bandyopadhyay AS, Self S, Rivera L, Saez-Llorens X, Lopez E, Melgar M, Gaensbauer JT, Weldon WC, Oberste MS, Borate BR, Gast C, Clemens R, Orenstein W, O'Ryan G M, Jimeno J, Clemens SA, Ward J, Rüttimann R; Latin American IPV001BMG Study Group.

Lancet. 2016 Jul 9;388(10040):158-69. doi: 10.1016/S0140-6736(16)00703-0. Epub 2016 May 19. Erratum in: Lancet. 2016 Jul 9;388(10040):e2.


Inactivated poliovirus vaccine given alone or in a sequential schedule with bivalent oral poliovirus vaccine in Chilean infants: a randomised, controlled, open-label, phase 4, non-inferiority study.

O'Ryan M, Bandyopadhyay AS, Villena R, Espinoza M, Novoa J, Weldon WC, Oberste MS, Self S, Borate BR, Asturias EJ, Clemens R, Orenstein W, Jimeno J, Rüttimann R, Costa Clemens SA; Chilean IPV/bOPV study group.

Lancet Infect Dis. 2015 Nov;15(11):1273-82. doi: 10.1016/S1473-3099(15)00219-4. Epub 2015 Aug 26. Erratum in: Lancet Infect Dis. 2015 Oct;15(10):1130.


Immunogenicity of a new routine vaccination schedule for global poliomyelitis prevention: an open-label, randomised controlled trial.

Sutter RW, Bahl S, Deshpande JM, Verma H, Ahmad M, Venugopal P, Rao JV, Agarkhedkar S, Lalwani SK, Kunwar A, Sethi R, Takane M, Mohanty L, Chatterjee A, John TJ, Jafari H, Aylward RB.

Lancet. 2015 Dec 12;386(10011):2413-21. doi: 10.1016/S0140-6736(15)00237-8. Epub 2015 Sep 18. Erratum in: Lancet. 2015 Dec 12;386(10011):2394.


Immunogenicity and safety of a novel monovalent high-dose inactivated poliovirus type 2 vaccine in infants: a comparative, observer-blind, randomised, controlled trial.

Sáez-Llorens X, Clemens R, Leroux-Roels G, Jimeno J, Clemens SA, Weldon WC, Oberste MS, Molina N, Bandyopadhyay AS.

Lancet Infect Dis. 2016 Mar;16(3):321-30. doi: 10.1016/S1473-3099(15)00488-0. Epub 2015 Dec 21.


Effect of a single inactivated poliovirus vaccine dose on intestinal immunity against poliovirus in children previously given oral vaccine: an open-label, randomised controlled trial.

John J, Giri S, Karthikeyan AS, Iturriza-Gomara M, Muliyil J, Abraham A, Grassly NC, Kang G.

Lancet. 2014 Oct 25;384(9953):1505-12. doi: 10.1016/S0140-6736(14)60934-X. Epub 2014 Jul 10.


Immunogenicity of three doses of bivalent, trivalent, or type 1 monovalent oral poliovirus vaccines with a 2 week interval between doses in Bangladesh: an open-label, non-inferiority, randomised, controlled trial.

Estívariz CF, Anand A, Gary HE Jr, Rahman M, Islam J, Bari TI, Wassilak SG, Chu SY, Weldon WC, Pallansch MA, Heffelfinger JD, Luby SP, Zaman K.

Lancet Infect Dis. 2015 Aug;15(8):898-904. doi: 10.1016/S1473-3099(15)00094-8. Epub 2015 Jun 17.


Community transmission of type 2 poliovirus after cessation of trivalent oral polio vaccine in Bangladesh: an open-label cluster-randomised trial and modelling study.

Taniuchi M, Famulare M, Zaman K, Uddin MJ, Upfill-Brown AM, Ahmed T, Saha P, Haque R, Bandyopadhyay AS, Modlin JF, Platts-Mills JA, Houpt ER, Yunus M, Petri WA Jr.

Lancet Infect Dis. 2017 Oct;17(10):1069-1079. doi: 10.1016/S1473-3099(17)30358-4. Epub 2017 Jul 7.


Human Circulating Antibody-Producing B Cell as a Predictive Measure of Mucosal Immunity to Poliovirus.

Dey A, Molodecky NA, Verma H, Sharma P, Yang JS, Saletti G, Ahmad M, Bahl SK, Wierzba TF, Nandy RK, Deshpande JM, Sutter RW, Czerkinsky C.

PLoS One. 2016 Jan 5;11(1):e0146010. doi: 10.1371/journal.pone.0146010. eCollection 2016.


Immunogenicity of poliovirus vaccines in chronically malnourished infants: a randomized controlled trial in Pakistan.

Saleem AF, Mach O, Quadri F, Khan A, Bhatti Z, Rehman NU, Zaidi S, Weldon WC, Oberste SM, Salama M, Sutter RW, Zaidi AK.

Vaccine. 2015 Jun 4;33(24):2757-63. doi: 10.1016/j.vaccine.2015.04.055. Epub 2015 Apr 24.


Effect of substituting IPV for tOPV on immunity to poliovirus in Bangladeshi infants: An open-label randomized controlled trial.

Mychaleckyj JC, Haque R, Carmolli M, Zhang D, Colgate ER, Nayak U, Taniuchi M, Dickson D, Weldon WC, Oberste MS, Zaman K, Houpt ER, Alam M, Kirkpatrick BD, Petri WA Jr.

Vaccine. 2016 Jan 12;34(3):358-66. doi: 10.1016/j.vaccine.2015.11.046. Epub 2015 Nov 28.


Inactivated polio vaccines from three different manufacturers have equivalent safety and immunogenicity when given as 1 or 2 additional doses after bivalent OPV: Results from a randomized controlled trial in Latin America.

Lopez-Medina E, Melgar M, Gaensbauer JT, Bandyopadhyay AS, Borate BR, Weldon WC, Rüttimann R, Ward J, Clemens R, Asturias EJ.

Vaccine. 2017 Jun 16;35(28):3591-3597. doi: 10.1016/j.vaccine.2017.04.041. Epub 2017 Apr 25.


Immunity status of adults and children against poliomyelitis virus type 1 strains CHAT and Sabin (LSc-2ab) in Germany.

Eggers M, Terletskaia-Ladwig E, Rabenau HF, Doerr HW, Diedrich S, Enders G, Enders M.

BMC Infect Dis. 2010 Dec 9;10:347. doi: 10.1186/1471-2334-10-347.


Polio eradication. Efficacy of inactivated poliovirus vaccine in India.

Jafari H, Deshpande JM, Sutter RW, Bahl S, Verma H, Ahmad M, Kunwar A, Vishwakarma R, Agarwal A, Jain S, Estivariz C, Sethi R, Molodecky NA, Grassly NC, Pallansch MA, Chatterjee A, Aylward RB.

Science. 2014 Aug 22;345(6199):922-5. doi: 10.1126/science.1255006.


Immunogenicity of bivalent types 1 and 3 oral poliovirus vaccine: a randomised, double-blind, controlled trial.

Sutter RW, John TJ, Jain H, Agarkhedkar S, Ramanan PV, Verma H, Deshpande J, Singh AP, Sreevatsava M, Malankar P, Burton A, Chatterjee A, Jafari H, Aylward RB.

Lancet. 2010 Nov 13;376(9753):1682-8. doi: 10.1016/S0140-6736(10)61230-5. Epub 2010 Oct 25.


Immunogenicity and safety evaluation of bivalent types 1 and 3 oral poliovirus vaccine by comparing different poliomyelitis vaccination schedules in China: A randomized controlled non-inferiority clinical trial.

Qiu J, Yang Y, Huang L, Wang L, Jiang Z, Gong J, Wang W, Wang H, Guo S, Li C, Wei S, Mo Z, Xia J.

Hum Vaccin Immunother. 2017 Jun 3;13(6):1-10. doi: 10.1080/21645515.2017.1288769. Epub 2017 Mar 1.


Comparison of IPV to tOPV week 39 boost of primary OPV vaccination in Indian infants: an open labelled randomized controlled trial.

Kanungo S, Kim DR, Haldar B, Snider C, Nalavade U, Kim SA, Park JY, Sinha A, Mallick AH, Manna B, Sur D, Nandy RK, Deshpande JM, Czerkinsky C, Wierzba TF, Petri WA Jr, Ali M, Dey A.

Heliyon. 2017 Jan 9;3(1):e00223. doi: 10.1016/j.heliyon.2016.e00223. eCollection 2017 Jan.


Systematic review of mucosal immunity induced by oral and inactivated poliovirus vaccines against virus shedding following oral poliovirus challenge.

Hird TR, Grassly NC.

PLoS Pathog. 2012;8(4):e1002599. doi: 10.1371/journal.ppat.1002599. Epub 2012 Apr 19. Review.


Intestinal immunity is a determinant of clearance of poliovirus after oral vaccination.

Wright PF, Wieland-Alter W, Ilyushina NA, Hoen AG, Arita M, Boesch AW, Ackerman ME, van der Avoort H, Oberste MS, Pallansch MA, Burton AH, Jaffar MA, Sutter RW.

J Infect Dis. 2014 May 15;209(10):1628-34. doi: 10.1093/infdis/jit671. Epub 2014 Jan 23.


Early priming with inactivated poliovirus vaccine (IPV) and intradermal fractional dose IPV administered by a microneedle device: A randomized controlled trial.

Anand A, Zaman K, Estívariz CF, Yunus M, Gary HE, Weldon WC, Bari TI, Steven Oberste M, Wassilak SG, Luby SP, Heffelfinger JD, Pallansch MA.

Vaccine. 2015 Nov 27;33(48):6816-22. doi: 10.1016/j.vaccine.2015.09.039. Epub 2015 Oct 23.


Supplemental Content

Support Center